Histotripsy, an innovative noninvasive cancer treatment, is making waves in the medical community. Developed by Zhen Xu at the University of Michigan and commercialized by HistoSonics, this technique uses powerful ultrasound to destroy tumors without heat or incisions. Recently, it received FDA approval for liver tumor treatment and shows promise for tackling pancreatic cancer.

Why This Matters

For years, the medical field viewed cavitation—the formation and collapse of tiny gas bubbles—as an unwelcome side effect of ultrasound. But in 2001, researchers at the University of Michigan began exploring its potential for destroying cancerous tumors. The challenge was controlling cavitation without generating harmful heat. Zhen Xu, then a Ph.D. student, discovered a method using extremely powerful ultrasound bursts to create and collapse bubbles, tearing apart tumor cells without damaging surrounding tissue.

This breakthrough has led to the development of histotripsy, a form of incisionless surgery. The technology has been commercialized by HistoSonics, a company Xu cofounded in 2009, with significant backing from investors like Jeff Bezos.

Key Details

The histotripsy technique involves delivering ultrasound in short, intense bursts, creating negative pressure that forms bubbles in the tissue. These bubbles collapse rapidly, turning the tissue into a slurry without heat buildup. This approach avoids the collateral damage associated with traditional surgical methods.

HistoSonics' Edison system, which utilizes this technology, received FDA approval in 2023 for liver tumors. The company is now eyeing regulatory approval for kidney cancer treatments and plans to launch a large-scale trial for pancreatic cancer.

The interdisciplinary nature of histotripsy is noteworthy, combining physics, biology, and engineering. Additionally, it stimulates immune responses, potentially enhancing the effectiveness of cancer treatments.

What Matters

• Noninvasive Revolution: Histotripsy offers a new way to treat tumors without surgery, radiation, or heat.
• FDA Approval: The green light for liver tumors marks a significant milestone in its clinical application.
• Interdisciplinary Innovation: Combines physics, biology, and engineering, showcasing the power of collaborative science.
• Immune Response: Stimulating the immune system could amplify treatment effects, opening new therapeutic avenues.
• Future Potential: With trials for other cancers underway, histotripsy could become a cornerstone in oncology.

Recommended Category

Research